<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040610</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 1401</org_study_id>
    <nct_id>NCT02040610</nct_id>
    <nct_alias>NCT02198222</nct_alias>
  </id_info>
  <brief_title>Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provision Center for Proton Therapy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Biomedical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Provision Center for Proton Therapy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being proposed to evaluate the use of moderate hypofractionated proton therapy&#xD;
      in low and intermediate risk prostate cancer patients. Quality of life outcomes as well as&#xD;
      gastrointestinal and genitourinary early and late toxicities will be analyzed and compared to&#xD;
      conventional proton therapy regimens. It is thought that this regimen will produce comparable&#xD;
      findings and would result in substantial health care cost savings, as well as, be more&#xD;
      convenient for patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive: 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to biochemical failure</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the freedom from biochemical failure survival outcomes (FFBF) and compare to historical FFBF results achieved following standard fractionation proton therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Assessment</measure>
    <time_frame>2 years &amp; 5 years</time_frame>
    <description>To determine the incidence of acute and late Gastrointestinal and Genitourinary toxicity at 2 and 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze Quality of Life</measure>
    <time_frame>2 years &amp; 5 years</time_frame>
    <description>To assess quality of life following proton therapy (QOL EPIC) at 2 and 5 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Salvage Androgen Deprivation Therapy</measure>
    <time_frame>Every 6 months for 5 years</time_frame>
    <description>To determine the need for salvage Androgen Deprivation Therapy for biochemical or other relapse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low Risk Prostate Cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk Prostate Cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Proton Therapy</intervention_name>
    <arm_group_label>Intermediate Risk Prostate Cancer</arm_group_label>
    <arm_group_label>Low Risk Prostate Cancer</arm_group_label>
    <other_name>Proton Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological (histologically) proven diagnosis of prostatic adenocarcinoma within 365&#xD;
             days (1 year) prior to study registration.&#xD;
&#xD;
               -  History and physical exam with digital rectal exam of the prostate to establish&#xD;
                  clinical staging&#xD;
&#xD;
               -  Clinical stage T1-T2c (AJCC 7th edition) within 90 days of registration.&#xD;
&#xD;
               -  Prostate specific antigen (PSA) &lt; 20 ng/mL within 90 days prior to registration.&#xD;
&#xD;
               -  Gleason Score &lt; 7.&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group(ECOG) Performance status 0-1.&#xD;
&#xD;
               -  Clinically negative lymph nodes evaluated by imaging (pelvic +/- abdominal CT or&#xD;
                  MRI scan).&#xD;
&#xD;
               -  Patients with lymph nodes equivocal or questionable by imaging are eligible&#xD;
                  without biopsy if the nodes are ≤ 1.5 cm in diameter; any node larger than this&#xD;
                  on imaging will require negative biopsy for eligibility, unless the node is know&#xD;
                  to be enlarged from prior scans and considered stable, per discretion of the&#xD;
                  treating physician.&#xD;
&#xD;
               -  Patients must be 18 years of age or older.&#xD;
&#xD;
               -  Patient must be able to provide study-specific informed consent prior to study&#xD;
                  entry.&#xD;
&#xD;
               -  Willingness and ability to complete the Expanded Prostate Cancer Index Composite&#xD;
                  (EPIC) Questionnaire.&#xD;
&#xD;
               -  No evidence of bone metastases (M0) on bone scan within 60 days prior to&#xD;
                  registration.&#xD;
&#xD;
               -  Bone scan is not required for patients enrolled with a single intermediate risk&#xD;
                  factor only, but this scan may be obtained at the discretion of the treating&#xD;
                  physician. Patients with 2 or 3 risk factors will require a negative bone scan&#xD;
                  for eligibility.&#xD;
&#xD;
               -  Equivocal bone scan findings are allowed if plain film x-rays are negative for&#xD;
                  metastasis.&#xD;
&#xD;
               -  Patient is able to start proton therapy or neo-adjuvant hormonal therapy, when&#xD;
                  recommended, within 12 weeks of registration.&#xD;
&#xD;
               -  No prior radiotherapy to the pelvic area.&#xD;
&#xD;
               -  No prior prostate cancer therapy such as: prostatectomy, cryotherapy,&#xD;
                  chemotherapy or hyperthermia.&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm3, Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3,&#xD;
                  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to&#xD;
                  achieve Hgb ≥ 8.0 g/dl is acceptable.)&#xD;
&#xD;
               -  Obs.: Patients with high risk factors, such as T3, Gleason 8-10 or PSA &gt; 20ng/mL&#xD;
                  who are not considered candidates for pelvic lymph node radiation treatment are&#xD;
                  still considered eligible for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Prior radiotherapy to the pelvic area.&#xD;
&#xD;
               -  Prior prostate cancer therapy such as: prostatectomy, cryotherapy, or&#xD;
                  hyperthermia.&#xD;
&#xD;
               -  Prior systemic therapy (chemotherapy) for prostate cancer.&#xD;
&#xD;
               -  Evidence of distant metastases.&#xD;
&#xD;
               -  Regional lymph node involvement.&#xD;
&#xD;
               -  Previous or concurrent cytotoxic chemotherapy for prostate cancer.&#xD;
&#xD;
               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease&#xD;
                  Control (CDC) definition. Note however, that HIV testing is not required for&#xD;
                  entry into this protocol. The need to exclude patients with AIDS from this&#xD;
                  protocol is necessary because the treatments involved in this protocol may be&#xD;
                  significantly immunosuppressive. Protocol-specific requirements may also exclude&#xD;
                  immune-compromised patients.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Ben Wilkinson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Provision Center for Proton Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie E Freeman, PhD</last_name>
    <phone>8659342672</phone>
    <email>natalie.freeman@biomed-research.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda J Whitehead, CCRP</last_name>
    <phone>8652433278</phone>
    <email>brenda.whitehead@biomed-research.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Provision Cares Proton Therapy Center Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie E Freeman, PhD</last_name>
      <phone>8659342672</phone>
      <email>natalie.freeman@biomed-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Whitehead, CCRP</last_name>
      <phone>8652433278</phone>
      <email>wil.rivers@biomed-research.com</email>
    </contact_backup>
    <investigator>
      <last_name>J. Ben Wilkinson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Meek, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Provision Cares Proton Therapy Center Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie E Freeman, PhD</last_name>
      <phone>865-934-2672</phone>
      <email>natalie.freeman@biomed-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Wil J Rivers, BS</last_name>
      <phone>6157164736</phone>
      <email>wil.rivers@biomed-research.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Risk Prostate Cancer</keyword>
  <keyword>Intermediate Risk Prostate Cancer</keyword>
  <keyword>Hypofractionated</keyword>
  <keyword>Image Guided Proton Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

